top of page

Free Biopharma Daily Stock Updates - 02/11/22

$XBI $93.35 | 1%

 

Covid Updates

$GILD Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022. source


PFE & BNTX Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age. source


$GILD Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies. source


NRXP Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine. source


$ABCL Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments. source


$NVAX First Administration of its COVID-19 Vaccine in Australia. source


Pipeline Updates

$PRQR Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10. source


$SPPI Acceptance of New Drug Application Filing for Poziotinib. source


$GILD Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults. source


$ORPH provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States. source


$ISEE Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy. source


$YMAB Completion of Pre-BLA Meeting with FDA for Omburtamab. source


$PASG PRESENTS NEW INTERIM CLINICAL DATA FOR PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY AT 2022 WORLDSYMPOSIUM. source


$OCUL UPCOMING PRESENTATION OF INTERIM OTX-TKI PHASE 1 CLINICAL TRIAL DATA AT ANGIOGENESIS, EXUDATION, AND DEGENERATION 2022 MEETING AND OTX-TIC PHASE 1 CLINICAL TRIAL AT GLAUCOMA 360. source


$LNTH Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting. source


Business Updates

$OBSN Licensing Agreement with Theramex for the Commercialization of Linzagolix. source


$DERM QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation. source


$MTCR Updates IBD Clinical Development Strategy and Implements Restructuring Plan. source


$LEGN Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen. source


$ADIL ANNOUNCES PRICING OF $10 MILLION REGISTERED DIRECT OFFERING. source


$ALVR Filed POS AM - amendment may offer and sell our Common Stock, Preferred Stock, Debt Securities, Warrants or Units, in each case in one or more issuances and at prices and on terms that we will determine at the time of the offering in an aggregate amount not to exceed $250,000,000 or the equivalent at the time of offering in any other currency. source


 

Posted by DV

0 comments
bottom of page